Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of astegolimab in frequently exacerbating COPD
MOH_2023-03-16_012339Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Astegolimab every 2 weeks, Astegolimab every 4 weeks alternating with placebo and Placebo every 2 weeks (3 arms). Started Mar 2023; status: active, not recruiting.
02
Drugs
astegolimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on MOH_2023-03-16_012339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-03-16_012339.